TaiGen Biopharmaceuticals Holdings Limited
Taipei Exchange 4157.TWO
TaiGen Biopharmaceuticals Holdings Limited Price to Earnings Ratio (P/E) on January 14, 2025: 52.47
-
TaiGen Biopharmaceuticals Holdings Limited 52-week high Price to Earnings Ratio (P/E) is 81.18 on April 19, 2024, which is 54.72% above the current Price to Earnings Ratio (P/E).
-
TaiGen Biopharmaceuticals Holdings Limited 52-week low Price to Earnings Ratio (P/E) is 52.41 on January 13, 2025, which is -0.12% below the current Price to Earnings Ratio (P/E).
-
TaiGen Biopharmaceuticals Holdings Limited average Price to Earnings Ratio (P/E) for the last 52 weeks is 70.92.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Mr. Kuo-Lung Huang |
| IPO Date | Aug. 30, 2013 |
| Location | Taiwan |
| Headquarters | No. 138, Xinming Road |
| Employees | 52 |
| Sector | Health Care |
| Industries | |
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.
Past 5 years
USD 0.93
USD 0.49
USD 0.93
USD 0.93
StockViz Staff
January 15, 2025
Any question? Send us an email